-
Case Report
-
Korean J Med. 2015;89(1):113-116. Published online July 1, 2015.
DOI: https://doi.org/10.3904/kjm.2015.89.1.113
- 혈액투석 환자에서 발생한 카포시육종의 Pazopanib 치료 증례
-
천유진, 최아란, 양서연, 김효은, 조장호, 임재윤, 조재용
-
연세대학교 의과대학 내과학교실
- Treatment of a Patient with Kaposi’s Sarcoma Arising during Hemodialysis with the Multikinase Inhibitor Pazopanib
-
You Jin Chun, Ah Ran Choi, Seo Yeon Yang, Hyo Eun Kim, Jang Ho Cho, Jae Yun Lim, Jae Yong Cho
-
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- Corresponding author: Jae Yong Cho ,Tel: +82-2-2019-4363, Fax: +82-2-3463-3882, Email: chojy@yuhs.ac
- Received: February 2, 2014; Revised: March 30, 2014 Accepted: September 22, 2014.
- 현재까지 우리나라에서는 본 증례를 포함해 아주 적은 수의 혈액투석 환자에서의 카포시육종이 보고되었으며, 특히 pazopanib을 첫 치료제로 선택한 경우는 보고된 바가 없다. 저자는 림프절병증을 동반한 카포시육종에서 pazopanib 복용 후 피부 병변 크기 감소 및 통증 완화의 치료 효과 있음을 경험하여 보고하고자 한다.
߽ɾ :Pazopanib; 카포시육종; 혈액투석
- Abstract
- Kaposi’s sarcoma (KS) is an unusual multifocal neoplastic angioproliferative disorder. We herein report a case of classic KS that occurred in a patient receiving hemodialysis for 7 years. The patient had a history of chronic renal failure due to glomerulonephritis for 20 years. Multiple reddened violaceous patches, plaques, and nodules were found on the right knee. Biopsy revealed positivity for human herpesvirus 8 (KS-associated herpesvirus) consistent with KS. Pazopanib, a multitarget tyrosine kinase inhibitor, is an effective agent for treatment of advanced soft tissue sarcoma. The patient received pazopanib for 6 months investigate its effects on KS. The skin lesions and painful symptoms showed improvement. Further studies are required to determine the mechanism underlying the anticancer action of pazopanib and the pathogenesis of KS.
Keywords :Pazopanib, Sarcoma, Kaposi, Renal dialysis
